Trials / Completed
CompletedNCT01349725
A Safety Study of ARRY-502 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a Phase 1 study, involving a 14-day dosing period, designed to test the safety of investigational study drug ARRY-502 in healthy subjects. Approximately 32 healthy subjects from the United States will be enrolled in this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARRY-502 | Oral; multiple dose, escalating |
| DRUG | Placebo | Oral; matching placebo |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2011-05-09
- Last updated
- 2020-10-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01349725. Inclusion in this directory is not an endorsement.